Live feed07:30:00·1430dPRReleasevia QuantisnowRegeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of CancerByQuantisnow·Wall Street's wire, on your screen.REGN· Regeneron Pharmaceuticals Inc.Health Care
